Tsujimoto S - Search Results

1

Cytotoxic mechanisms of FK317, a new class of bioreductive agent with potent antitumor activity.

Naoe Y, Inami M, Kawamura I, Nishigaki F, Tsujimoto S, Matsumoto S, Manda T, Shimomura K. Naoe Y, et al. Among authors: tsujimoto s. Jpn J Cancer Res. 1998 Jun;89(6):666-72. doi: 10.1111/j.1349-7006.1998.tb03269.x. Jpn J Cancer Res. 1998. PMID: 9703365 Free PMC article.

2

Effects of FK317, a novel anti-cancer agent, on survival of mice bearing B16BL6 melanoma and Lewis lung carcinoma.

Inami M, Kawamura I, Tsujimoto S, Nishigaki F, Matsumoto S, Naoe Y, Sasakawa Y, Matsuo M, Manda T, Goto T. Inami M, et al. Among authors: tsujimoto s. Cancer Lett. 2002 Jul 8;181(1):39-45. doi: 10.1016/s0304-3835(02)00044-7. Cancer Lett. 2002. PMID: 12430177

3

FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome.

Naoe Y, Inami M, Matsumoto S, Nishigaki F, Tsujimoto S, Kawamura I, Miyayasu K, Manda T, Shimomura K. Naoe Y, et al. Among authors: tsujimoto s. Cancer Chemother Pharmacol. 1998;42(1):31-6. doi: 10.1007/s002800050781. Cancer Chemother Pharmacol. 1998. PMID: 9619755

4

Different effects of FK317 on multidrug-resistant tumor in vivo and in vitro.

Naoe Y, Inami M, Takagaki S, Matsumoto S, Kawamura I, Nishigaki F, Tsujimoto S, Manda T, Shimomura K. Naoe Y, et al. Among authors: tsujimoto s. Jpn J Cancer Res. 1998 Oct;89(10):1047-54. doi: 10.1111/j.1349-7006.1998.tb00495.x. Jpn J Cancer Res. 1998. PMID: 9849584 Free PMC article.

5

FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.

Naoe Y, Inami M, Matsumoto S, Takagaki S, Fujiwara T, Yamazaki S, Kawamura I, Nishigaki F, Tsujimoto S, Manda T, Shimomura K. Naoe Y, et al. Among authors: tsujimoto s. Jpn J Cancer Res. 1998 Dec;89(12):1306-17. doi: 10.1111/j.1349-7006.1998.tb00528.x. Jpn J Cancer Res. 1998. PMID: 10081492 Free PMC article.

6

Anti-cachectic effect of FK317, a novel anti-cancer agent, in colon26 and LX-1 models in mice.

Naoe Y, Kawamura I, Inami M, Matsumoto S, Nishigaki F, Tsujimoto S, Manda T, Shimomura K. Naoe Y, et al. Among authors: tsujimoto s. Jpn J Cancer Res. 1998 Dec;89(12):1318-25. doi: 10.1111/j.1349-7006.1998.tb00529.x. Jpn J Cancer Res. 1998. PMID: 10081493 Free PMC article.

7

FR177391, a new anti-hyperlipidemic agent from Serratia. II. Pharmacological activity of FR177391.

Inami M, Kawamura I, Tsujimoto S, Yasuno T, Lacey E, Hirosumi J, Takakura S, Nishigaki F, Naoe Y, Manda T, Mutoh S. Inami M, et al. Among authors: tsujimoto s. J Antibiot (Tokyo). 2005 Oct;58(10):640-7. doi: 10.1038/ja.2005.88. J Antibiot (Tokyo). 2005. PMID: 16392680

8

A new aromatase inhibitor, FR901537. II. Pharmacological and antitumor effects.

Oohata N, Kawamura I, Lacey E, Nishigaki F, Matsumoto S, Tsujimoto S, Naoe Y, Manda T, Shimomura K. Oohata N, et al. Among authors: tsujimoto s. J Antibiot (Tokyo). 1995 Aug;48(8):763-7. doi: 10.7164/antibiotics.48.763. J Antibiot (Tokyo). 1995. PMID: 7592018 Free article.

9

Potentiation of the toxicity of tumor necrosis factor by tumors in mice.

Nishigaki F, Miyayasu K, Tsujimoto S, Manda T, Shimomura K. Nishigaki F, et al. Among authors: tsujimoto s. Circ Shock. 1994 Oct;44(2):77-83. Circ Shock. 1994. PMID: 7743604

10

Role of tissue factor in the antitumor effect of recombinant human tumor necrosis factor-alpha in mice.

Nishigaki F, Miyayasu K, Tsujimoto S, Manda T, Shimomura K. Nishigaki F, et al. Among authors: tsujimoto s. Anticancer Res. 1994 Nov-Dec;14(6B):2573-6. Anticancer Res. 1994. PMID: 7872683

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

302 results

Search Page

Filters